COMMUNIQUÉS West-GlobeNewswire

MMI Raises $125M in Series D to Accelerate Commercial Growth of the Symani Surgical System Worldwide
08/10/2026
Financing will support market expansion, expand access, and advance the clinical evidence needed to broaden the role of robotic microsurgery JACKSONVILLE, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) -- MMI (Medical [...]
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
08/10/2026
TEL AVIV, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that an additional presentation highlighting [...]
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
08/10/2026
Three scientific presentations will highlight new analyses of VOQUEZNA ® (vonoprazan) in GERD, including real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in Erosive Esophagitis [...]
Enovis to Host Third Quarter 2026 Results Conference Call on November 5th
08/10/2026
Dallas, TX, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to [...]
Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
08/10/2026
Advancing Precision Oncology and Partner-Ready Therapeutic Programs Through Capital-Efficient Development PHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), [...]
Spirair Announces Publication of Multicenter Study Demonstrating Significant Six-Month Improvements with SeptAlign
08/10/2026
Six-month Vayu Study results published in Laryngoscope Investigative Otolaryngology 63 percent reduction in NOSE scores One-day median return to work 97 percent of patients would recommend the procedure to friends or [...]
ViroMissile Appoints Diane Simeone, M.D., and Matt Mulvey, Ph.D. as Advisors
08/10/2026
Appointments add scientific, clinical, and business depth as three Phase 1 intravenously-dosed oncolytic viral programs advance in the clinic SAN DIEGO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- ViroMissile, Inc., a cancer [...]
Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
08/10/2026
Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last year Performance reflects continued [...]
Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
08/10/2026
LIBERTY CORNER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company, today announced that the United States Patent and [...]
Bluesight’s 2026 Diversion Trends Report Shows Hospital Diversion Programs Maturing as Technology Use Expands
08/10/2026
ALEXANDRIA, VA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Annual report finds software and AI adoption increasing as dedicated staffing tightens, while compliance and human reporting remain critical to diversion prevention [...]
Iantrek Expands Clinical Evidence for Bio-Interventional Ophthalmic Surgery Across Trabecular and Uveoscleral Outflow Pathways
08/10/2026
Six-month data on a new bio-reinforced canaloplasty procedure show 37% IOP reduction; new findings on bio-reinforced cyclodialysis to be presented at AAO 2026 WHITE PLAINS, N.Y., Oct. 08, 2026 (GLOBE NEWSWIRE) -- [...]
Solu Therapeutics Initiates Dosing in Acute Myeloid Leukemia Cohort of the Ongoing Phase 1 Study of STX-0712
08/10/2026
BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced that [...]
Ritedose Opens Advanced Laboratory and Expands Analytical Capabilities to Accelerate Pharmaceutical Innovation—Positioning the Company as a Preferred Partner for Drug Development and Manufacturing
08/10/2026
Triples laboratory footprint with the $17 million investment. Features new leachables and extractables testing capabilities. Allows for seamless development and manufacturing experience while supporting pharmaceutical [...]
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
08/10/2026
NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will [...]
Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
08/10/2026
New criteria fully approved at nine of eleven active sites expected to significantly accelerate enrollment pace Initial readout timing to be updated by year-end based on demonstrated Q4 enrollment increases Overall [...]
What Actually Keeps Weight Off After a Weight Loss Program
08/10/2026
Baltimore, MD, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Weight regain after initial weight loss is a recognized pattern among individuals pursuing lasting metabolic change. Trilivy™, a science-backed, coach-guided metabolic [...]
Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET
08/10/2026
CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, [...]
Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
08/10/2026
Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety and tolerability [...]
Newron Provides Update on FDA Clinical Hold and Phase 3 ENIGMA-TRS Development Program
08/10/2026
Management call today at 3.30 pm CEST Newron received the anticipated FDA written communication on clinical hold at U.S. study centers and is reviewing feedback and preparing its response ENIGMA-TRS 1 enrollment [...]

Pages